Login   |   Register
Source: Wikipedia


Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects

Paola Ulivi, Daniele Calistri, Wainer Zoli, Dino Amadori

Authors information
  • Paola Ulivi
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy, Italy. p.ulivi@irst.emr.it
  • Daniele Calistri
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy, Italy.
  • Wainer Zoli
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy, Italy.
  • Dino Amadori
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy, Italy.

Abstract


In recent years, a number of novel agents have been investigated that target specific molecular pathways in non-small cell lung cancer (NSCLC). A great deal of effort has been focused on identifying specific markers that predict treatment response, given that a tailored approach would maximize both the therapeutic index and the cost-effectiveness. The epidermal growth factor receptor (EGFR) pathway has emerged as a key regulator of cancer cell proliferation and invasion, and several specific EGFR inhibitors have been examined. Gefitinib and erlotinib are selective EGFR tyrosine kinase inhibitors (EGFR-TKIs), demonstrating good results in selected cases both in terms of objective response rate and of overall survival. At present, EGFR gene mutations are the best positive predictive factors for TKI therapy, and a number of other potential biomarkers are being investigated as additional positive or negative predictors of response. The correct selection of patients that could benefit from these innovative therapies, based on an accurate molecular characterization, is mandatory to provide the best clinical management. Currently, the main factor limiting the characterization of metastatic NSCLC patients is the small quantity of tumor cells available for molecular analysis. In this paper we provide an overview of the most important molecular predictive markers for EGFR-TKIs therapy in NSCLC patients, and focus attention on biological samples suitable for analysis and alternative sampling approaches such as plasma- or serum-derived DNA.

Keywords


NSCLC; EGFR- TKIs; plasma/serum; predictive markers;

Full Text





Submitted: 2010-04-13 10:24:39
Published: 2010-07-15 14:13:55
Search for citations in Google Scholar
Related articles: Google Scholar


 

The Journal of Nucleic Acids Investigation [eISSN 2035-6005] is an Open Access, peer-reviewed journal published by PAGEPress, Pavia, Italy. All credits and honors to PKP for their OJS.

 

 
 
© PAGEPress 2008-2014     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185